Please login to the form below

Not currently logged in
Email:
Password:

Thomas Shenk leaves Merck board to focus on forthcoming antiviral company

Aims to commercialise research work carried out at Princeton University

Thomas Shenk - formerly of MerckThomas Shenk has retired from Merck & Co's board of directors after 11 years.

He has left to focus on a new business build on his work with Princeton University, where he has been Elkins Professor in the department of molecular biology since 1984 and served as chairman of the department from 1996 to 2004.

His forthcoming company will aim to commercialise discoveries in the field of antiviral therapy made at his Princeton laboratory.

Shenk's research includes work with fellow academic Ileana Cristea to research sirtuins – enzymes that can stem viral infections.

The broad antiviral activity of sirtuins indicates they can be used to treat a number of viral diseases.

A provisional patent application has been filed by Shenk and Cristea on known sirtuin agonists and several dual antagonists as broad spectrum antiviral therapeutics.

Shenk is also director of the Fox Chase Cancer Center – a Philadelphia-based hospital specialising in the treatment, research and prevention of cancer – and editor-in-chief for The Journal of Virology.

10th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics